Latest Content

European survey reveals how oncology nurses manage complex multiple myeloma care amid time and resource constraints.

Leslie Smith, DNP, discusses mediating trial care, vetting protocols for nursing scope of practice, and guiding frontline nurses toward research.

Erika Hamilton, MD, breaks down liver monitoring, diarrhea, creatinine shifts, and oral adherence with maintenance tucatinib in HER2+ MBC.

ABUS matched handheld ultrasound on cancer detection in women with dense breasts while lowering recall and short-interval follow-up rates.

Long-term QUILT-3.032 data in BCG-unresponsive NMIBC with CIS show durable responses for some patients and a long, surveillance-heavy course.

The approval in stage II/III MSI-H/dMMR rectal cancer rests on AZUR-1, in which 71% of patients needed no treatment beyond dostarlimab.

Dr. Andrew Pecora on leading the first IV oncolytic virus trial, building a top-50 cancer center, and using AI to fix the cost of cancer care.

Eppie Bass, APRN, explains how nurses can counsel patients on flu-like symptoms vs warning signs with nogapendekin alfa inbakicept-pmln and BCG.

Discover how equine-assisted services support patients with cancer by improving emotional wellness, building confidence, and enhancing quality of life.

A Moffitt nurse practitioner explains rollout, handling, triage, and patient education for nogapendekin alfa inbakicept-pmln plus BCG.

Life table analysis estimates residual ovarian cancer risk by current age and planned age at risk-reducing surgery.

Nogapendekin alfa inbakicept-pmln plus BCG now covers high-grade papillary-only disease, based on extrapolation from CIS efficacy data.

FDA-approved subcutaneous isatuximab via on-body injector changes myeloma care workflows. Experts outline what nurses and PAs need to know.